Marc C Chamberlain1. 1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of Southern Florida, Neuro-Oncology Program, Tampa, Florida 33612, USA. chambemc@moffitt.usf.edu
Abstract
BACKGROUND: Neoplastic meningitis (NM) is a common problem in neuro-oncology, occurring in approximately 5% of all patients with cancer. REVIEW SUMMARY: Notwithstanding frequent focal signs and symptoms in NM, NM is a disease affecting the entire neuraxis, and therefore staging and treatment need encompass all cerebrospinal fluid (CSF) compartments. RESULTS: Central nervous system (CNS) staging of NM includes contrast-enhanced cranial computed tomography (CE-CT) or magnetic resonance imaging (MR-Gd), contrast-enhanced spine magnetic resonance imaging (MR-S) or computed tomographic myelography (CT-M), and radionuclide CSF flow study (FS). Treatment of NM incorporates involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to 3 chemotherapeutic agents (ie, methotrexate, cytosine arabinoside, and thio-TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. CONCLUSIONS: Although treatment of NM is palliative, with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM.
BACKGROUND:Neoplastic meningitis (NM) is a common problem in neuro-oncology, occurring in approximately 5% of all patients with cancer. REVIEW SUMMARY: Notwithstanding frequent focal signs and symptoms in NM, NM is a disease affecting the entire neuraxis, and therefore staging and treatment need encompass all cerebrospinal fluid (CSF) compartments. RESULTS: Central nervous system (CNS) staging of NM includes contrast-enhanced cranial computed tomography (CE-CT) or magnetic resonance imaging (MR-Gd), contrast-enhanced spine magnetic resonance imaging (MR-S) or computed tomographic myelography (CT-M), and radionuclide CSF flow study (FS). Treatment of NM incorporates involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to 3 chemotherapeutic agents (ie, methotrexate, cytosine arabinoside, and thio-TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. CONCLUSIONS: Although treatment of NM is palliative, with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM.
Authors: Marine Boudot de la Motte; Rachid Abbas; Fanny Jouan; Damien van Gysel; Marie Paule Chauveheid; Thomas Papo; Karim Sacre Journal: Clin Med (Lond) Date: 2018-03 Impact factor: 2.659
Authors: Priscilla K Brastianos; Harry C Brastianos; Wesley Hsu; Daniel M Sciubba; Thomas Kosztowski; Betty M Tyler; Violette Renard Recinos; Peter Burger; Stuart A Grossman Journal: J Neurooncol Date: 2011-07-26 Impact factor: 4.130
Authors: E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain Journal: J Neurooncol Date: 2013-03-01 Impact factor: 4.130
Authors: Morris D Groves; Kenneth R Hess; Vinay K Puduvalli; Howard Colman; Charles A Conrad; Mark R Gilbert; Jeffrey Weinberg; Massimo Cristofanilli; W K Alfred Yung; Ta-Jen Liu Journal: J Neurooncol Date: 2009-03-07 Impact factor: 4.130